Pulse Biosciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Kevin Danahy
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | no data |
| CEO ownership | 0.06% |
| Management average tenure | 2.8yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
May 16We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
May 10
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$44m |
| Mar 31 2024 | n/a | n/a | -US$43m |
| Dec 31 2023 | US$6m | US$433k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$2m | US$350k | -US$59m |
Compensation vs Market: Kevin's total compensation ($USD5.86M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
CEO
Kevin Danahy (53 yo)
no data
Tenure
US$5,864,450
Compensation
Mr. Kevin P. Danahy is Principal Executive Officer of Pulse Biosciences, Inc. from December 6, 2024 and serves as its Chief Commercial Officer since May 14, 2024. He was Chief Executive Officer of Pulse Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 7.1yrs | US$257.41k | 69.3% $ 760.1m | |
| Chief Commercial Officer & Principal Executive Officer | no data | US$5.86m | 0.059% $ 651.4k | |
| CTO, Principal Financial Officer & Director | 2.3yrs | US$5.39m | 0.25% $ 2.7m | |
| Chief Strategy Officer | 3.3yrs | US$1.69m | 0.23% $ 2.5m | |
| Vice President of Operations | 7.7yrs | no data | no data | |
| Chief Science Officer | 10.1yrs | no data | no data | |
| General Counsel & Corporate Secretary | 3.6yrs | no data | no data | |
| Vice President of Human Resources | 4.9yrs | no data | no data | |
| Senior Vice President of Engineering | 3.3yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | no data | |
| Chief Science Officer of Cardiac Surgery | 1.2yrs | no data | no data | |
| Chief Medical Officer of Electrophysiology | less than a year | no data | no data |
2.8yrs
Average Tenure
58yo
Average Age
Experienced Management: PLSE's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Co-Chairman | 7.1yrs | US$257.41k | 69.3% $ 760.1m | |
| CTO, Principal Financial Officer & Director | 9.3yrs | US$5.39m | 0.25% $ 2.7m | |
| Independent Director | 4.3yrs | US$208.89k | 0% $ 0 | |
| Independent Co-Chairman of the Board | less than a year | no data | no data | |
| Independent Director | 7.8yrs | US$173.00k | 1.32% $ 14.5m | |
| Lead Independent Director | 7.1yrs | US$180.07k | 0% $ 0 |
7.1yrs
Average Tenure
58yo
Average Age
Experienced Board: PLSE's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 06:04 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |
| Christopher Cooley | Stephens, Inc. |